Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Demant ASWILYY 94 EV-to-EBIT is 20.63 as of Jul. 25, 2026, which is 10% below its 10-year median of 22.83. GuruFocus rates WILYY with a GF Score™ of 94/100 and a GF Value™ of $23.90 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 465 Medical Devices & Instruments companies, Demant AS ranks worse than 58.28% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Demant AS's Enterprise Value for the quarter that ended in Dec. 2025 was $10,007 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Demant AS's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $569 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Demant AS EV-to-EBIT Related Terms
Demant AS EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Demant AS's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Demant AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Demant AS EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Demant AS's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Demant AS's EV-to-EBIT falls into.
Demant AS's current Enterprise Value is $11,734 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Demant AS's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $569 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Demant AS (WILYY) has a EV-to-EBIT of 20.63 as of Jul. 25, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Demant AS and its competitors. This is 10% below median its historical median of 22.83. Over the past decade, Demant AS's EV-to-EBIT has ranged from 13.86 to 68.82. According to the industry distribution chart, Demant AS ranks #271 out of 465 companies in the Medical Devices & Instruments industry, placing it in the top 58.3%.
Is Demant AS's EV-to-EBIT too high?
Demant AS's current EV-to-EBIT of 20.63 is 10% below median its 10-year median of 22.83. Over the past 10 years, this metric has ranged from a low of 13.86 to a high of 68.82. The Medical Devices & Instruments industry median EV-to-EBIT is 18.19. Demant AS's value of 20.63 is 13.4% above this industry median. Based on the distribution chart, Demant AS ranks #271 out of 465 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Demant AS has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Demant AS's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Demant AS ranks #271 out of 465 companies for EV-to-EBIT. This places Demant AS in the lower half of its industry. The industry median EV-to-EBIT is 18.19. Demant AS's value of 20.63 is 13.4% above this benchmark. Historically, Demant AS's own EV-to-EBIT has ranged from 13.86 to 68.82 over the past decade. While the company's 10-year median is 22.83 vs. the industry median of 18.19, Demant AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.19, based on 465 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Demant AS's current EV-to-EBIT of 20.63 is 13.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Demant AS and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Demant AS's current EV-to-EBIT is 20.63, which is 10% below median its own 10-year median of 22.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Demant AS stock overvalued right now?
Based on GuruFocus' analysis, Demant AS (WILYY) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.90, compared to a current price of $20.66 — trading 13.6% below its estimated fair value. The current EV-to-EBIT is 20.63, which is 10% below median its 10-year median of 22.83 and 13.4% above the Medical Devices & Instruments industry median of 18.19. Demant AS's overall GF Score™ is 94/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Demant AS (WILYY), the current EV-to-EBIT is 20.63 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Demant AS (WILYY) Overvalued in 2026?
Based on GuruFocus' analysis, Demant AS stock appears to be undervalued.
The current stock price of $20.66 is trading 13.6% below its estimated GF Value™ of $23.90.
GuruFocus considers Demant AS to be Modestly Undervalued.
Key valuation signals for WILYY:
EV-to-EBIT: 20.63 (10% below median its 10-year median of 22.83)
GF Value™: $23.90 vs. price of $20.66 (13.6% below fair value)
Industry Position: 13.4% above the Medical Devices & Instruments median (#271 of 465)
No single metric tells the full story. See the WILYY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Demant is a Denmark-based manufacturer and distributor of hearing solutions, such as hearing aid devices and diagnostic equipment. More than 80% of the company's sales come from North America and Europe.
94GF Score
Get the complete analysis for WILYY
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WILYY has been successfully added to your 
